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Background. A recombinant BCG strain expressing the genetically detoxified S1 subunit of pertussis toxin 9K/129G (rBCG-S1PT),
previously constructed by our research group, demonstrated the ability to develop high protection in mouse models of pertussis
challengewhich correlatedwith the induction of aTh1 immune response pattern.TheTh1 immune response induced by rBCG-S1PT
treatment was also confirmed in the murine orthotopic bladder cancer model, in which the intravesical instillation of rBCG-S1PT
resulted in an improved antitumor effect. Based on these observations, we hypothesize that the reengineering of the S1PT expression
in BCGcould increase the efficiencyof the protectiveTh1 immune response in order to develop a new alternative of immunotherapy
in bladder cancer treatment. Objectives. To construct rBCG strains expressing S1PT from extrachromosomal (rBCG-S1PT) and
integrative vectors (rBCG-Sli), or their combination, generating the bivalent strain (rBCG-S1+S1i), and to evaluate the respective
immunogenicity of rBCG strains in mice. Methods. Mycobacterial plasmids were constructed by cloning the s1pt gene under
integrative and extrachromosomal vectors and used to transform BCG, individually or in combination. Antigen expression and
localization were confirmed by Western blot. Mice were immunized with wild-type BCG or the rBCG strains, and cytokines
quantification and flow cytometry analysis were performed in splenocytes culture stimulated with mycobacterial-specific proteins.
Findings. S1PT expression was confirmed in all rBCG strains. The extrachromosomal vector directs S1PT to the cell wall-associated
fraction, while the integrative vector directs its expressionmainly to the intracellular fraction.Higher levels of IFN-𝛾were observed
in the splenocytes culture from the group immunized with rBCG-S1i in comparison to BCG or rBCG-S1PT. rBCG-S1+S1i showed
higher levels of CD4+ IFN-𝛾+ and double-positive CD4+ IFN-𝛾+ TNF-𝛼+ T cells. Conclusions. rBCG-S1+S1i was able to express
the two forms of S1PT and elicited higher induction of polyfunctional CD4+ T cells, indicating enhanced immunogenicity and
suggesting its use as immunotherapy for bladder cancer.
1. Introduction
The Bacillus Calmette-Guérin (BCG) vaccine was developed
almost a century ago and since then has been used against
tuberculosis being the responsible for saving millions of lives
worldwide. In addition to tuberculosis control, the benefits
of BCG vaccination are also related to nonspecific protection
against other infectious diseases [1]. BCG is also awell-known
agent for the therapeutic treatment of bladder cancer. The
intravesical instillation with BCG has been widely used as
clinical treatment against superficial bladder carcinoma in
situ for decades, reaching 60% of effectiveness [2]. Although
the antitumor mechanisms of BCG are complex, it is well
established that a Th1 profile with production of proinflam-
matory cytokines such as IFN-𝛾 and TNF-𝛼 is correlated with
the protective action and the success of the treatment [2, 3].
Several studies used BCG as a live vector to express a
variety of viral, bacterial, and parasite antigens [4]. rBCG
strains has been generated by the expression of antigens
through a variety of different strategies [5] including dual
promoters [6], fused antigens [7], multiple integrations into
the mycobacterial genome [8], and promoter engineering
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[9] or as an operon [10]. It was demonstrated that rBCG
strains expressing Th1 cytokines induced higher cytotoxicity
of PBMCs in vitro against bladder tumor cell lines [11, 12].
In the murine orthotopic bladder cancer model, mice treated
with rBCG secreting IFN-𝛾 showed higher survival rates in
comparison to mice treated with BCG carrying the empty
vector [13].
Previous work in our laboratory led to the construction of
a recombinant BCG strain expressing the genetically detox-
ified S1 subunit of pertussis toxin 9K/129G (rBCG-S1PT)
for use as a neonatal vaccine against pertussis. This vaccine
showed promising results in the protection against an intrac-
erebral challenge with lethal dose of Bordetella pertussis.
Furthermore, mice immunized with rBCG-S1PT also showed
induction of an increased Th1 immune response against
mycobacterial proteins in comparison to mice immunized
with wild-type BCG [14–16]. Based on these studies, our
group evaluated the therapeutic application of rBCG-S1PT
in an orthotopic model of murine bladder cancer. In com-
parison to wild-type BCG, rBCG-S1PT induced increased
expression of TNF-𝛼 and IL-10, promoted the reduction of
bladder tumor development, and showed higher survival of
animals [17, 18].
Since the increased antitumor activity of rBCG-S1PT
was related to its ability to induce an effective Th1 immune
response, we hypothesize that the differential expression of
S1PT could improve the immunotherapeutic effectiveness of
rBCG.The aim of this work was to construct and evaluate the
immunogenicity of rBCG strains expressing S1PT through
single (extrachromosomal or integrative vectors) and bivalent
expression systems (combination of both single expressions).
2. Material and Methods
2.1. Ethics. Female BALB/c mice (5 to 8 weeks old) were
supplied by the Animal Housing Facility of the Butantan
Institute and housed under adequate conditions according
to the ethical committee. This study was approved under the
protocol 1178/14.
2.2. Cloning Procedure. All cloning steps were performed
in Escherichia coli DH5𝛼 strain (Invitrogen) transformed by
heat shock and transformants grown in LB in the presence of
kanamycin (20 𝜇g/mL) for selection. Briefly, the lysA cassette
of expression in the integrative plasmid pBRL8 was removed
by digesting with Cla I and Not I, treated with Klenow and
religated. Then, the genetically detoxified S1 gene sequence
(s1pt) was PCR amplified using primers s1-forward 5’-
TAGCATATGGACGATCCTCCCGCCACCGTATA – 3’ and
s1-reverse 5’- TAGATCGATGAACGAATACGCGATGCTTT
and cloned under the regulation of the PL5 promoter at Nde I
and Pvu II sites, thus generating pBRL-S1 (Figure 1).
The correct insertion of s1pt was confirmed by Sanger
sequencing using primer PL5-f 5’-TAGGTTTAAACAAAC-
GGAAACAGCTATGACCAT-3’.
2.3. BCG Transformation. BCG Moreau strain was grown
in Middlebrook 7H9 supplemented with OADC (MB7H9)
under 5% CO2 at 37
∘C and electrocompetent cells prepared
according to previous protocol [19]. Competent BCG was
transformed with pBRL-S1 and clones selected by resistance
to kanamycin inMiddlebrook 7H10 plates supplementedwith
OADC and kanamycin (MB7H10). A single clone of rBCG-
S1i was used to confirm S1 expression under the integrative
plasmid. To generate the bivalent strain (rBCG-S1+S1i) a
previously generated lysine auxotrophic BCG (rBCG-ΔlysA)
complemented with pNL71S1-lysA was electroporated with
pBRL-S1. In this report, the complemented auxotroph rBCG-
ΔlysA-S1PT-lysA+ (kan−) strain, which expresses S1PT under
𝑝𝐵𝑙𝑎𝐹∗ promoter fused with the signal sequence of 𝛽-
lactamase, is referred to as rBCG-S1PT.
2.4. Western Blotting. To confirm the expression of the S1PT
antigen in rBCG-S1PT, rBCG-S1i, and rBCG-S1+S1i, the
rBCG strains were grown in MB7H9 until mid-log phase
when cells where centrifuged and washed twice with PBS.
Cells were resuspended in PBS and lysed by sonication. Total
protein extracts were separated by centrifugation into soluble
and insoluble fractions and separated by SDS-PAGE. Protein
extractswere electrotransferred to a PVDFmembrane using a
semidry electroblotter (Owl Separation Systems) and blocked
with 5% nonfat dry milk solution for 16 h at 4∘C. Mouse
polyclonal anti-S1PT generated in-house (1:1,000) was used
for antigen detection incubating the membrane for 2 h.
The secondary antibody, goat anti-IgG HRP was incubated
at 1:2,000 for 1 h (A6782, Sigma). Peroxidase reaction was
detected using the ECL Prime Detection Reagent (GE) and
a LAS4000 photoimaging equipment (GE).
2.5. Plasmid Stability. rBCG-S1i and rBCG-S1+S1i which
possess resistance to kanamycin were grown in 5 mL of
MB7H9 without antibiotic until late-log phase. 100 𝜇L of the
culture was used for serial passaging up to 8 times in the same
medium without antibiotic. After every passage an aliquot
of the culture was used to seed MB7H10 plates with and
without kanamycin. Plasmid stability was determined by the
percentage of colonies able to grow in the medium with and
without kanamycin.
2.6. Vaccine Preparation and Immunization. Single clones
of wild-type BCG, rBCG-S1PT, rBCG-S1i, and rBCG-S1+S1i
were grown in 50 mL of MB7H9 until mid-log phase and
centrifuged. Mycobacteria were washed twice with 10% ice-
cold glycerol, and aliquots were resuspended in 10% glycerol
and maintained at -80∘C until use. For immunization, cell
concentration was adjusted to 107 CFU/mL and 100 𝜇L
used for intraperitoneal immunization of groups of mice (5
mice/group).
2.7. Phenotype and Cytokine Release of Spleen Cells. Thirty
days after the single dose immunization, spleens of immu-
nized mice were recovered and cell suspensions were pre-
pared using a Wheaton tissue grinder. Cell suspensions (5
x 106 cells/mL) were cultured in RPMI-1640 supplemented
with 10% fetal bovine serum (Invitrogen) and polymyxin B
(250 ng/mL). Cells were stimulated with previously prepared
mycobacterial culture filtrate proteins CFP (5 𝜇g/well) [19],
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Figure 1: Schematic of cloning and generation of bivalent recombinant BCG strain. pBRL8 vector was digested with NotI/ClaI to remove
lysA cassette (STEP 1) and the s1pt gene was PCR amplified and cloned under PL5 promoter thus generating pBRL-S1 vector (STEP 2). This
vector was used to transform wild-type BCG (STEP 3) thus generating rBCG-S1i. In the STEP 4, rBCG-S1PT wasmade electrocompetent and
used in a 2nd transformation step with pBRL-S1 to generate the bivalent strain.
Concanavalin A (5 𝜇g/mL, Sigma), or left unstimulated for 48
h at 37∘C in 5% CO2. The culture supernatants were collected
and cytokine levels were quantified using the Cytometric
Bead Array Th1/Th2/Th17 kit (BD Bioscience) or ELISA
(Peprotech), according to manufacturer’s recommendations.
For phenotypical characterization of spleen cells, they were
cultured for 4 h at 37∘C in 5% CO2 and incubated with
monensin (BD Bioscience) according to the manufacturer’s
instructions. Cells were fixed and stained with the following
antibodies: anti-CD3-APC-Cy7, anti-CD4-PE-Cy5, TNF-𝛼-
FITC, and IFN-𝛾-APC, and samples were acquired on a
FACSCanto II flow cytometer (BD Bioscience) and analyzed
using the Flow Jo software (Tree Star).
2.8. Statistical Analysis. Mann-Whitney two-way Student’s t
test was used to evaluate the significant differences between
groups for cytokine release experiments. Unpaired one-way
Student’s t test was used to evaluate the differences between
stimulated and nonstimulated cells for the phenotypic char-
acterization of CD4+ T cells.
3. Results
3.1. Single and Bivalent Expression of S1PT in Recombinant
BCG. The expression of S1PT in BCG through the integrative
vector (rBCG-S1i) was confirmed by Western blot. Protein
extracts of rBCG-S1i showed a single immunoreactive band




































Figure 2: Bivalent expression of S1PT antigen in recombinant BCG. Western blot of rBCG strains expressing S1PT through distinct vectors.
Protein extracts of wild-type BCG (BCGwt), rBCG-S1PT, rBCG-S1i and rBCG-S1+S1i were separated in soluble and insoluble fractions. S1PT
antigen was detected using anti-S1PT previously generated in mice. The values in the center represent the molecular sizes in kilodaltons.
Arrows indicate the presence of the two forms of S1PT expressed in rBCG.
in the expected size in both soluble and insoluble fractions
(Figure 2). The rBCG-S1i strain displays a band that runs
slightly lower than the rBCG-S1PT strain. The protein in the
rBCG-S1PT includes a fusion of the antigen with the signal
sequence of𝛽-lactamase (∼ 3 kDa), a feature of the expression
cassette of the pNL71 vector. As expected, the expression
through the integrative vector showed a lower level of S1PT
than the extrachromosomal vector (Figure 2). In the bivalent
construct, it is possible to distinguish two bands representing
the expression of S1PT with and without the signal sequence.
The protein in fusion with the 𝛽-lactamase’s signal sequence
was directed mostly to the cell wall-associated fraction, while
the protein expressed from the integrative vector, without
this feature, was concentrated in the intracellular fraction
(Figure 2).
3.2. Plasmid Stability. We evaluated the stability of the inte-
grative plasmid in the single and bivalent constructs (rBCG-
S1i and rBCG-S1+S1i strains, respectively) without antibi-
otic pressure. Serial passages showed 67% of kanamycin-
resistant colonies in rBCG-S1i throughout eight passages,
while rBCG-S1+S1i displayed 88% of kanamycin-resistant
colonies (Figure 3).These results indicate that the integration
is relatively stable in vitro.
3.3. Cytokine Production by Splenocytes fromMice Immunized
with the rBCG Constructs. Groups of mice were immu-
nized with a single dose of BCG, rBCG-S1PT, rBCG-S1i,
or rBCG-S1+S1i. Four weeks later, spleen cells were isolated
for quantification of TNF-𝛼 and IFN-𝛾 production in cul-
ture supernatant following stimulation with mycobacterial
proteins contained in CFP. All BCG strains induced higher
levels of IFN-𝛾 and TNF-𝛼 in comparison to the saline group
(Figure 4).The rBCG-S1i group showed a significantly higher
level of IFN-𝛾 in comparison to wild-type BCG and rBCG-
S1PT (Figure 4). IL-10, IL-4, and IL-2 were detected at very
low levels (data not shown).
3.4. CD4+ T Cell Phenotype of Splenocytes from Immunized
Mice. To further characterize the immunogenicity induced
by these vaccines, we investigated the phenotypic profile of
CD4+ T cells recovered from the spleen through analysis of


















Figure 3: In vitro stability of bivalent rBCG construct. rBCG-
S1i and rBCG-S1+S1i were serially passaged in MB7H10 plates
with and without kanamycin and the percentage of CFU retaining
kanamycin resistance (Kan R+) was determined according to CFU
quantification.
of mice immunized with BCG or rBCGs strains showed a
significant increase in the percentage of CD4+IFN-𝛾+ T cells
when stimulated with CFP, in comparison to nonstimulated
cells (Figure 5(a)). Furthermore, wild-type BCG and rBCG-
S1+S1i induced a significant increase in the percentage of
CD4+TNF-𝛼+ T cells (Figure 5(b)). Moreover, only rBCG-
S1+S1i group showed a ∼ 2-fold higher percentage of double-
positive CD4+IFN-𝛾+TNF-𝛼+ T cells as compared with
the nonstimulated cells (Figure 5(c)). On the other hand,
the comparative analysis between CFP-stimulated groups
showed that only rBCG-S1+S1i generated significantly higher
CD4+IFN-𝛾+ and CD4+IFN-𝛾+TNF-𝛼+ T cells (Figures 5(d)
and 5(f)).
4. Discussion
There aremany studieswhich have developed rBCGs express-
ing exogenous antigens from several pathogens (such as













































































Figure 4: Single integrative and bivalent rBCG vaccines induce inflammatory cytokines. Splenocytes from immunized mice were cultured
for 48 h in presence of CFP or medium only (mock). Cytokine levels were measured by ELISA. Data are shown as the mean (±SEM) from n
= 4-5 mice per group. Statistical analyses were performed by Student’s t test with a Mann-Whitney post-test. ∗𝑝 < 0.05, ∗∗𝑝 < 0.01; ns = not
significant.
viruses, bacteria, and parasites) based on the idea of improv-
ing the strength of immune response activation through
the combination of the immunological recognition against
BCG (as live vector) and the foreign antigen expressed
by the recombinant mycobacteria [20]. The expression of
different antigens in BCG can modify the immunological
properties of BCG and the antigen. Furthermore, the level of
expression and localization of the antigen are also important
factors in the immunogenicity induced by the strains [21].
We have obtained rBCG strains expressing the same antigen
from different expression vectors, in an effort to increase
the immunogenicity of the BCG strains expressing S1PT
for further use as an alternative immunotherapy to murine
bladder cancer model.
In this study, we showed that through the transformation
of BCGwith the integrative vector and the extrachromosomal
plasmid, the rBCG-S1+S1i strain was indeed able to express
the two forms of the S1PT antigen. Interestingly, we also
demonstrated that the antigen was mainly produced by the
extrachromosomal plasmid in the rBCG-S1+Sli strain. This is
an expected feature since the extrachromosomal plasmid can
maintain several copies per cell while the integrative vector
comprises only one copy. Additionally, we also observed a
distinct level of S1PT in soluble and insoluble fractions.While
the extrachromosomal plasmid concentrated S1PT mainly in
the insoluble fraction (cell wall-associated fraction), the inte-
grative vector directed its expression to the soluble fraction
(intracellular). This clearly indicates the functionality of the
𝛽-lactamase exportation signal in these constructs [22].
Another factor that can influence the immune response
induced by rBCG strains is vector stability. In the absence
of the antibiotic pressure, some constructs tend to lose the
plasmid and consequently the expression of the heterologous
antigen [21]. Our results demonstrated that the use of two
expression systems did not affect the stability of the rBCG
constructs. Both rBCG-S1i and rBCG-S1+S1i displayed a
high proportion of kanamycin-resistant colonies, even after 8
passages in liquid culture, an indication that the integrative
plasmid pBRL-S1i was present. Since the medium used to
grow rBCG-S1+S1i was not supplemented with lysine, we
can suppose that colonies also maintained the pNL71S1-lysA
plasmid.
All groups of immunizedmice showed an increased num-
ber of CD4+ T cells producing IFN-𝛾 when stimulated with
CFP. However, we observed that rBCG-S1+S1i can induce
a distinct immune response. Only rBCG-S1+S1i induced an
increased percentage of CD4+ IFN-𝛾+ and CD4+ IFN-𝛾+
TNF-𝛼+ T cells, in comparison to the other rBCG strains.
Polyfunctional T cells are known to be important for bladder
cancer treatment. The combination of 𝛼-PD-1 and 𝛼-CTLA-
4 can suppress tumor development by T cell infiltration
into tumors and the induction of polyfunctional effector
tumor infiltrating lymphocytes (TIL), probably CD4+ and
CD8+ T cells [23]. Others demonstrated that patients with
tumor recurrence showed significative reduction of CD4+
T cells compared to nonrecurrence patients. Moreover, the
frequency of IFN-𝛾 and TNF-𝛼+ producing CD4+ T cells was
significantly lower in patients compared to healthy controls
[24], which shows that these cells are targets for bladder
immunotherapy.
Our results show the possibility of immunomodula-
tion by the bivalent expression of S1PT in rBCG, allowing
enhanced Th1 immune response induced in mice, especially
by the induction of polyfunctional CD4+ T cell responses.
This study further reinforces the use of rBCG strains as an
alternative in the bladder cancer therapy.







































































































































































































Figure 5: Bivalent recombinant BCG (rBCG-S1+Sli) vaccine induces higher percentage of polyfunctional CD4+T cells. Splenocytes from
immunized mice were cultured for 18 h in the presence of CFP or medium only (mock) and stained with anti-CD3-APC-Cy7, anti-CD4-PE-
Cy5, TNF-𝛼-FITC and IFN-𝛾-APC for flow cytometry analysis. (A-C): percentage of CD4+ IFN-𝛾+, CD4+ TNF-𝛼+ andCD4+ IFN-𝛾+ TNF-𝛼+
T cells are expressed as a fold-change increase after stimulus. (D-F): percentage of CD4+ IFN-𝛾+, CD4+ TNF-𝛼+ and CD4+IFN-𝛾+ TNF-𝛼+
T cells in stimulated splenocytes from immunized mice. The bars represent the differences obtained between stimulated (in the presence of
CFP) and non-stimulated (mock). ∗𝑝 < 0.05∗∗𝑝 < 0.01; ns = not significant.
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